Study Details

Participation Requirements

Age

18 Years +

Sex

All

Healthy Volunteers

Medical Condition

Solid Tumor

Gender

N/A

Date

December 2017 - June 2021

Study Type

Interventional

Study Phase

Phase 1

Product

KITE-718, Cyclophosphamide, Fludarabine, MAGE - A3/A6 Screening Test

Eligibility Information

Inclusion Criteria

Age ≥ 18 years
Advanced cancer defined as relapsed or refractory disease after a systemic standard of care treatment regimen and, if available, at least one standard of care salvage regimen unless the subject refuses such therapy. Multiple myeloma (MM) subjects must have had both a protease inhibitor (PI) and immunomodulatory drugs (IMiD) as part of the last regimen, or at least 3 prior lines of therapy, including a PI and an IMiD. Additionally, subjects must not have disease amenable to definitive locoregional therapy.
MAGE-A3/A6 positive tumor as confirmed by the central laboratory
HLA-DPB1*04:01 positive
At least 1 measurable lesion on CT or MRI
No evidence of central nervous system (CNS) disease by MRI or CT of the brain. Note: Prior brain metastasis which have been treated with definitive therapy are eligible provided that the definitive therapy was completed more than six months prior to screening.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Toxicities due to prior therapy must be recovered to baseline or ≤ grade 1, except for clinically non-significant toxicities such as alopecia
Adequate bone marrow function as evidenced by:
Absolute neutrophil count (ANC) ≥ 1000/mm^3
Platelet ≥ 100/mm^3
Hemoglobin > 8 g/dL
Adequate renal, hepatic, cardiac, and pulmonary function as evidenced by:
Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 cc/min (24-hour urine creatinine clearance is also acceptable)
Alanine transaminase (ALT)/aspartate aminotransferase (AST) ≤ 2.5 x upper limit normal (ULN) or ≤ 5 x ULN if documented liver metastases
Total bilirubin ≤ 1.5 mg/dL
Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion as determined by an ECHO, and no clinically significant ECG findings (For ejection fraction only, MUGA scan is also acceptable)
No clinically significant pleural effusion
Baseline oxygen saturation > 92% on room air

Exclusion Criteria

Malignancy other than non-melanoma skin cancer, carcinoma in situ, or low grade prostate cancer for which watch-and-wait approach is standard of care, unless disease free for at least 3 years
Clinically significant cardiac disease within last 12 months
Stroke or transient ischemic attack (TIA) within 12 last months
Symptomatic deep vein thrombosis or pulmonary embolism within last 6 months, catheter associated thrombosis is not included as exclusion criteria.
Prior T-cell therapy, including KITE-718 or MAGE-A3/A6-targeting therapy.
Live vaccine ≤ 4 weeks prior to enrollment
Systemic corticosteroid therapy within 7 days before enrollment.
History of severe, immediate hypersensitivity reaction attributed to aminoglycosides
Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management.
Presence of any indwelling line or drain. Note: Dedicated central venous access catheters such as a Port-a-Cath or Hickman catheter as well as feeding tubes such as a G-tube, are permitted.
Primary immunodeficiency
Autoimmune disease resulting in end-organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years prior to enrollment.
Known history of infection with HIV, hepatitis B (HBsAg positive), or hepatitis C (anti-HCV positive). A history of treated hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative polymerase chain reaction (PCR) and/or nucleic acid testing.
Females who are pregnant as confirmed by a positive serum or urine pregnancy test or are breastfeeding.
Individuals of both genders of child-bearing potential who are not willing to practice birth control from the time of consent through 6 months after the completion of KITE-718
Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Locations

Locations (12)

Banner MD Anderson Cancer Center

Gilbert, Arizona, United States, 85234

USC/Norris Comprehensive Cancer Center

Los Angeles, California, United States, 90033

UCLA Hematology/Oncology

Los Angeles, California, United States, 90095

University of California Davis Comprehensive Cancer Center

Sacramento, California, United States, 95817

H. Lee Moffitt Cancer and Research Institute

Tampa, Florida, United States, 33612

University of Chicago

Chicago, Illinois, United States, 60640

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Icahn School of Medicine at Mount Sinai

New York, New York, United States, 10029

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

Baylor Scott & White Charles A. Sammons Cancer Center

Dallas, Texas, United States, 75246

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

University of Utah, Huntsman Cancer Institute

Salt Lake City, Utah, United States, 84112

Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers

OVERVIEW

PROTOCOL SUMMARY